Approaches to Increase Equitable Access to and Delivery of Quality of Care with Bispecific Antibodies for Patients with Multiple Myeloma 2023
Closing dates:
- Topic: Support for the funding of projects that promote quality of care and best practice in the treatment of patients with relapsed/refractory Multiple Myeloma receiving treatment with a biospecific antibody.
- Founder: Pfizer, S.A.
- Budget: 1,250,000€, of which 250,000€/project will be awarded.
- Duration: maximum 2 years.
- Internal deadline: 30 May 2023.
- Deadline: 1 June 2023.
- Web link
- Bases of the call
